CN107501367A - The O β D glucuronic acids butyl esters of chrysoeriol 7 and its extracting method and purposes - Google Patents
The O β D glucuronic acids butyl esters of chrysoeriol 7 and its extracting method and purposes Download PDFInfo
- Publication number
- CN107501367A CN107501367A CN201710792154.2A CN201710792154A CN107501367A CN 107501367 A CN107501367 A CN 107501367A CN 201710792154 A CN201710792154 A CN 201710792154A CN 107501367 A CN107501367 A CN 107501367A
- Authority
- CN
- China
- Prior art keywords
- chrysoeriol
- butyl ester
- acid butyl
- water
- aldehydic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCCCOC([C@]([C@]([C@]([C@@]1*)O)O)O[C@]1Oc(cc1OC(c(cc2OC)ccc2O)=C2)cc(O)c1C2=O)=O Chemical compound CCCCOC([C@]([C@]([C@]([C@@]1*)O)O)O[C@]1Oc(cc1OC(c(cc2OC)ccc2O)=C2)cc(O)c1C2=O)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/07—Benzo[b]pyran-4-ones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of O β D glucuronic acid butyl esters of chrysoeriol 7, the structural formula of the O β D glucuronic acid butyl esters of chrysoeriol 7 is：The invention also discloses a kind of extracting method of O β D glucuronic acid butyl esters of chrysoeriol 7 and its application on anti-oxidation medicine, antioxidation cosmetic product, hypoglycemic drug or antineoplastic is prepared.
Description
Technical field
The present invention relates to a kind of compound and its extracting method and purposes.It is more particularly related to a kind of gold is holy
Straw colour element -7-O- β-D-Glucose aldehydic acid butyl ester and its extracting method and purposes.
Background technology
Triangle bubble steeps the dry of (Cardiospermum halicacabum L.) for Sapindaceae cardiospermum halicacabum platymiscium triangle
Dry herb, also known as balloonvine heartseed herb, wind ship barge.The ground such as Guangdong, Guangxi, Fujian, Taiwan are mainly distributed on, its acrid flavour, are trembled with fear, are had clear
Heat, diuresis, cool blood, dissolving stasis, removing toxic substances and other effects, it is used for treating pneumonia, jaundice, gonorrhoea, furunculosis, rheumatism, traumatic injury, snakeworm
The illness such as bite.Modern pharmacological research shows, triangle bubble with anti-inflammatory, anti-oxidant, analgesia, antipyretic, anti-malarial, antidiarrheal, diuresis,
Anti-diabetic, anticonvulsion, antianxiety etc. act on.In recent years, triangle bubble research at home and abroad cause extensive concern, seminar opens
Triangle bubble related basic research has been opened up, has as a result found that triangle bubble ethanol total extract can significantly reduce alloxan diabetes mouse
With the blood glucose value of adrenaline diabetic mice；Joint is fed with high-sugar-fat-diet low dose of chain arteries and veins assistant rhzomorph is injected intraperitoneally
(STZ) diabetes B rat model is established, it is n-butanol portion to determine the most strong position of anti-diabetes B activity, but its anti-2 type
The research of diabetic activity composition and mechanism is quite shallow.Therefore, this problem combines tcm clinical practice and traditional Chinese medical theory, with Chinese medicine
Methods and techniques, the hypoglycemic most strongly active position (n-butanol portion) of confrontation diabetes B carry out systematic research.It is intended to
By following the trail of isolated active component, its active principle recognition mode is established, to illustrate the drug effect that triangle steeps hypoglycemic effect
The principle of material base and compound compatibility provides scientific basis, and base is established for the discovery of blood-sugar decreasing active and lead compound
Plinth, steep quality standard for lifting triangle and establish material base, guidance is provided for its formulation development and quality control, it is anti-to illustrate it
The mechanism that disease is cured the disease provides scientific basis.
The content of the invention
It is an object of the invention to solve at least the above, and provide the advantages of at least will be described later.
It is a still further object of the present invention to provide a kind of chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester and its extraction
Method and purposes, it is extracted from natural plants triangle bubble, has good antioxidation and hypoglycemic effect.
In order to realize according to object of the present invention and further advantage, there is provided a kind of chrysoeriol -7-O- β-D-
Glucuronic acid butyl ester, the structural formula of the chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester are：
Based on above-mentioned technical proposal, the invention also discloses a kind of chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester
Extracting method, comprise the following steps：
1) coarse powder is steeped as raw material using triangle, ethanol is solvent, is extracted using percolation, distilled alcohol solvent, is obtained
First medicinal extract；
2) into first medicinal extract plus water, form suspension, sequentially added into suspension petroleum ether, ethyl acetate,
N-butanol is extracted, and concentration butanol extraction liquid is into medicinal extract, as the second medicinal extract；
3) second medicinal extract is taken, carries out polyamide column chromatography separation, using water-ethanol as eluant, eluent, carries out gradient elution,
The eluent of 50% ethanol water is collected, 50% ethanol water eluent of concentration obtains medicinal extract, as the 3rd medicinal extract；
4) the 3rd medicinal extract is taken, carries out polyamide column chromatography separation, using water-methanol as eluant, eluent, carries out gradient elution,
The eluent of 60% methanol-water is collected, is concentrated to give yellow powder, yellow pin is obtained through silica gel column chromatography separation and acetone recrystallization
Shape crystallizes, as target product chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester.
Preferably, the extracting method of described chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester, in step 1),
The volume fraction of ethanol is 50~95%, and the usage amount of alcohol solvent steeps 8~15 times of coarse powder weight for triangle.
Preferably, the extracting method of described chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester, in step 2),
The temperature of extraction is 60-90 DEG C.
Preferably, the extracting method of described chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester, in step 3),
Using water and ethanol as eluant, eluent, gradient elution is carried out, 5 gradients is specifically divided into and is eluted, the volume ratio of water and ethanol is successively
For：100:0、100:30、100:50、100:80、100:95.
Preferably, the extracting method of described chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester, in step 4),
Using water-methanol as eluant, eluent, gradient elution is carried out, is specifically divided into and is eluted for 6 gradients, the volume ratio difference of water and methanol
For：100:0、100:20、100:40、100:60、100:80、0:100.
Preferably, the extracting method of described chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester, in step 4),
Silica gel column chromatography is separated using chloroform and methanol as eluant, eluent, is carried out gradient elution, is specifically divided into 2 gradients and is eluted,
Its volume ratio is respectively：7:1 and 3:1.
Based on above-mentioned technical proposal, the invention also discloses a kind of chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester
Purposes, the chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester preparing anti-oxidation medicine, antioxidation cosmetic product, drop
Application in hypoglycemic medicament or antineoplastic.
The present invention comprises at least following beneficial effect：The present invention extracts chrysoeriol -7-O- β-D- Portugals from triangle bubble
Grape alditol acid butyl ester, easy extraction, recovery rate is higher, and the compound has good antioxidation and drop blood
Sugar effect.
Further advantage, target and the feature of the present invention embodies part by following explanation, and part will also be by this
The research and practice of invention and be understood by the person skilled in the art.
Brief description of the drawings
Fig. 1 is chrysoeriol -7-O- β of the present invention-D-Glucose aldehydic acid butyl ester1H-NMR spectrum；
Fig. 2 is chrysoeriol -7-O- β of the present invention-D-Glucose aldehydic acid butyl ester13C-NMR spectrograms；
Fig. 3 is the HMQC spectrograms of chrysoeriol -7-O- β of the present invention-D-Glucose aldehydic acid butyl ester；
Fig. 4 is the HMBC spectrograms of chrysoeriol -7-O- β of the present invention-D-Glucose aldehydic acid butyl ester；
Fig. 5 is the HRESI-MS mass spectrograms of chrysoeriol -7-O- β of the present invention-D-Glucose aldehydic acid butyl ester；
Fig. 6 is the HMBC dependency diagrams of chrysoeriol -7-O- β of the present invention-D-Glucose aldehydic acid butyl ester.
Embodiment
The present invention is described in further detail below in conjunction with the accompanying drawings, to make those skilled in the art with reference to specification text
Word can be implemented according to this.
It should be noted that experimental method described in following embodiments, is conventional method unless otherwise specified, institute
Reagent and material are stated, unless otherwise specified, is commercially obtained.
Embodiment 1：
A kind of chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester, the chrysoeriol -7-O- β-D-Glucose aldehyde
The structural formula of acid butyl ester is：
A kind of extracting method of chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester, comprises the following steps：
1) coarse powder is steeped as raw material using triangle, ethanol is solvent, is extracted using percolation, distilled alcohol solvent, is obtained
First medicinal extract；
2) into first medicinal extract plus water, form suspension, sequentially added into suspension petroleum ether, ethyl acetate,
N-butanol is extracted, and concentration butanol extraction liquid is into medicinal extract, as the second medicinal extract；
3) second medicinal extract is taken, carries out polyamide column chromatography separation, using water-ethanol as eluant, eluent, carries out gradient elution,
The eluent of 50% ethanol water is collected, 50% ethanol water eluent of concentration obtains medicinal extract, as the 3rd medicinal extract；
4) the 3rd medicinal extract is taken, carries out polyamide column chromatography separation, using water-methanol as eluant, eluent, carries out gradient elution,
The eluent of 60% methanol-water is collected, is concentrated to give yellow powder, yellow pin is obtained through silica gel column chromatography separation and acetone recrystallization
Shape crystallizes, as target product chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester.
Wherein, in step 1), the volume fraction of ethanol is 60%, and the usage amount of alcohol solvent steeps coarse powder weight for triangle
10 times.
Wherein, in step 2), the temperature of extraction is 60 DEG C.
Wherein, in step 3), using water and ethanol as eluant, eluent, gradient elution is carried out, 5 gradients is specifically divided into and is washed
De-, the volume ratio of water and ethanol is followed successively by：100:0、100:30、100:50、100:80、100:95.
Wherein, in step 4), using water-methanol as eluant, eluent, gradient elution is carried out, is specifically divided into and is washed for 6 gradients
De-, the volume ratio of water and methanol is respectively：100:0、100:20、100:40、100:60、100:80、0:100.
Wherein, in step 4), silica gel column chromatography is separated using chloroform and methanol as eluant, eluent, carries out gradient elution, tool
Body is divided into 2 gradients and eluted, its volume ratio (chloroform：Methanol) be respectively：7:1 and 3:1.
The recovery rate of chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester is 88.5% in the present embodiment.
Embodiment 2：
A kind of chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester, the chrysoeriol -7-O- β-D-Glucose aldehyde
The structural formula of acid butyl ester is：
A kind of extracting method of chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester, comprises the following steps：
1) coarse powder is steeped as raw material using triangle, ethanol is solvent, is extracted using percolation, distilled alcohol solvent, is obtained
First medicinal extract；
2) into first medicinal extract plus water, form suspension, sequentially added into suspension petroleum ether, ethyl acetate,
N-butanol is extracted, and concentration butanol extraction liquid is into medicinal extract, as the second medicinal extract；
3) second medicinal extract is taken, carries out polyamide column chromatography separation, using water-ethanol as eluant, eluent, carries out gradient elution,
The eluent of 50% ethanol water is collected, 50% ethanol water eluent of concentration obtains medicinal extract, as the 3rd medicinal extract；
4) the 3rd medicinal extract is taken, carries out polyamide column chromatography separation, using water-methanol as eluant, eluent, carries out gradient elution,
The eluent of 60% methanol-water is collected, is concentrated to give yellow powder, yellow pin is obtained through silica gel column chromatography separation and acetone recrystallization
Shape crystallizes, as target product chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester.
Wherein, in step 1), the volume fraction of ethanol is 80%, and the usage amount of alcohol solvent steeps coarse powder weight for triangle
12 times.
Wherein, in step 2), the temperature of extraction is 80 DEG C.
Wherein, in step 3), using water and ethanol as eluant, eluent, gradient elution is carried out, 5 gradients is specifically divided into and is washed
De-, the volume ratio of water and ethanol is followed successively by：100:0、100:30、100:50、100:80、100:95.
Wherein, in step 4), using water-methanol as eluant, eluent, gradient elution is carried out, is specifically divided into and is washed for 6 gradients
De-, the volume ratio of water and methanol is respectively：100:0、100:20、100:40、100:60、100:80、0:100.
Wherein, in step 4), silica gel column chromatography is separated using chloroform and methanol as eluant, eluent, carries out gradient elution, tool
Body is divided into 2 gradients and eluted, its volume ratio (chloroform：Methanol) be respectively：7:1 and 3:1.
The recovery rate of chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester is 90.7% in the present embodiment.
Embodiment 3：
A kind of chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester, the chrysoeriol -7-O- β-D-Glucose aldehyde
The structural formula of acid butyl ester is：
A kind of extracting method of chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester, comprises the following steps：
1) coarse powder is steeped as raw material using triangle, ethanol is solvent, is extracted using percolation, distilled alcohol solvent, is obtained
First medicinal extract；
2) into first medicinal extract plus water, form suspension, sequentially added into suspension petroleum ether, ethyl acetate,
N-butanol is extracted, and concentration butanol extraction liquid is into medicinal extract, as the second medicinal extract；
3) second medicinal extract is taken, carries out polyamide column chromatography separation, using water-ethanol as eluant, eluent, carries out gradient elution,
The eluent of 50% ethanol water is collected, 50% ethanol water eluent of concentration obtains medicinal extract, as the 3rd medicinal extract；
4) the 3rd medicinal extract is taken, carries out polyamide column chromatography separation, using water-methanol as eluant, eluent, carries out gradient elution,
The eluent of 60% methanol-water is collected, is concentrated to give yellow powder, yellow pin is obtained through silica gel column chromatography separation and acetone recrystallization
Shape crystallizes, as target product chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester.
Wherein, in step 1), the volume fraction of ethanol is 95%, and the usage amount of alcohol solvent steeps coarse powder weight for triangle
15 times.
Wherein, in step 2), the temperature of extraction is 90 DEG C.
Wherein, in step 3), using water and ethanol as eluant, eluent, gradient elution is carried out, 5 gradients is specifically divided into and is washed
De-, the volume ratio of water and ethanol is followed successively by：100:0、100:30、100:50、100:80、100:95.
Wherein, in step 4), using water-methanol as eluant, eluent, gradient elution is carried out, is specifically divided into and is washed for 6 gradients
De-, the volume ratio of water and methanol is respectively：100:0、100:20、100:40、100:60、100:80、0:100.
Wherein, in step 4), silica gel column chromatography is separated using chloroform and methanol as eluant, eluent, carries out gradient elution, tool
Body is divided into 2 gradients and eluted, its volume ratio (chloroform：Methanol) be respectively：7:1 and 3:1.
The recovery rate of chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester is 91.9% in the present embodiment.
The compound that the present inventor extracts according to embodiment 3 carries out representational experiment, draws the compound1H-
NMR spectra as shown in figure 1,13C-NMR spectrograms as shown in Fig. 2 HMQC spectrograms as shown in figure 3, HMBC spectrograms as shown in figure 4,
HRESI-MS mass spectrograms are as shown in figure 5, the HMBC correlations of the compound are as shown in Figure 6.
A kind of chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester (Chrysoeriol-7-O- β-D-glucuronide
Butyl ester), its structural formula is as follows：
Its molecular formula is：C26H28O12；
Its relative molecular weight is：532.4933；
The HRESI-MS mass spectrometric datas of the compound are 555.1567 [M-Na]+；
The compound13C-NMR compose and1H-NMR composes related data, as shown in table 1.
Chrysoeriol -7-O- the β of table 1.-D-Glucose aldehydic acid butyl ester13C-NMR compose and1H-NMR composes related data
In order to illustrate the antioxidation activity of the compounds of this invention, DPPH systems Oxidation Resistance Test will be carried out and remove ABTS certainly
By the measure of base ability, illustrate the excellent antioxidant effect of the compounds of this invention.
Experiment material：
DPPH (hexichol is for bitter taste free acyl radical), ABTS [2,2'- hydrazines-bis- (3- ethyl benzo thiazole phenanthroline -6- sulphurs
Acid)], (BHT), Trolox (watermiscible vitamin E).
Experimental method：
DPPH system Oxidation Resistance Tests：Compound concentration is 0.5mmol/L DPPH working solutions, takes 100 μ L to be added to 96 orifice plates
In.Each sample proportional diluted is separately added into the systems of 100 μ L mono- into 7 concentration (1.6~0.012 5mmol/L), then each hole
Row sample solution and positive drug (Trolox) solution, it is placed in dark place reaction 25min.After reaction completely, enzyme is used under 517nm wavelength
Mark instrument detection absorbance (A) value.DPPH clearance rates are calculated according to formula.
Clearance rate=(A blank-A samples)/A blank
Each concentration sets 3 multiple holes, DPPH Scavenging activity IC50Represent.
ABTS is tested and FRAP experimental implementations are carried out with reference to the specification of kit.ABTS experimental results are equivalent with Trolox
Oxidation resistance represents that is, Trolox TAC is 1, in the case of same concentrations, the oxidation resistance of other materials
The multiple compared with its oxidation resistance with Trolox.FRAP experimental results FeSO4The concentration of standard liquid represents, i.e., single
The sample of site concentration is equivalent to FeSO4The oxidation resistance of standard liquid.
Experimental result：
1st, experimental result is shown：Test medicine group (preparation of embodiment 1,2,3) is to DPPH free radicals, ABTS+Free radical is equal
There is scavenging action, and clearance rate has certain relation with extract concentrations.Test medicine group (preparation of embodiment 1,2,3) performance it is existing compared with
Strong antioxidation activity.It the results are shown in Table 2.
The antioxidation activity of the test medicine of table 2.
| Test medicine group | DPPH/(mmol.L-1) | ABTS | FRAP/(mmol·L-1) |
| Positive controls | 0.478 | — | 4.198 |
| Embodiment 1 | 0.516 | 1.338 | 5.421 |
| Embodiment 2 | 0.486 | 1.368 | 5.656 |
| Embodiment 3 | 0.498 | 1.342 | 5.851 |
| Triangle steeps coarse powder | 1.142 | 0.657 | 3.792 |
In order to illustrate the function of polysaccharide of the compound of the present invention, present inventor has performed chrysoeriol -7-O- β-D- Portugals
The measure of the external alpha-glucosidase activity of grape alditol acid butyl ester.
Experiment material：
Microplate reader ELX808TM types ELIASA (BioTek companies of the U.S.), DAS makes
(Origin softwares), acarbose (56180, Central China Hai Wei (Beijing) Gene Tech. Company Limited).
Experimental method：
1) preparation of inhibitor storing solution：The inhibitor tested is made into 10mM DMSO solution.
2) preparation of enzyme stock solution：Alpha-glucosidase is purchased from Sigma Co., USA；With pH=6.8 phosphate-buffered
Liquid is made into 1mg/mL respectively.
3) preparation of Substrate stock liquid：P-nitrophenyl glucoside (PNPG) is substrate, purchased from Sigma companies；Use pH=
6.8 phosphate buffer is made into 10mg/mL respectively.
4) preparation of terminate liquid：Sodium carbonate (Na2CO3) it is purchased from Shanghai traditional Chinese medicines；Distinguished with pH=6.8 phosphate buffer
It is made into 0.1M Na2CO3Solution.
5) test：The volume tested every time is all 200 μ L pH=6.8 phosphate buffer.
10 μ L various concentrations inhibitor solutions are separately added into 96 hole elisa Plates and (use pH=6.8 phosphate buffer solutions
Dilute inhibitor storing solution), with pH=6.8 phosphate buffer solutions polishing to 170 μ L, 10 μ L enzyme stock solutions are then added,
10min is incubated in 37 DEG C of ELIASA, 20 μ L Substrate stock liquid is added immediately, surveys it after mixing immediately one point at λ=405nm
Clock absorbance change (slope).Reference liquid is pH=6.8 phosphate buffer solutions.
6) result judges：100 unit of activity are used as not to be loaded the absorbance change (slope) measured by product；With respect to enzyme
Vigor=(add inhibitor absorbance change (slope)/without addition inhibitor absorbance change (slope) × 100, when
The concentration of inhibitor when the relative activity of enzyme is 50 is the IC of inhibitor50Value, the results are shown in Table 3.
Compound chrysoeriol -7-O- the β of table 3.-D-Glucose aldehydic acid butyl ester is to alpha-glucosaccharase enzyme inhibition activity
IC50Value
Chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester is to alpha-glucosidase from the results shown in Table 3
Inhibitory activity (IC50=5.67 μM) it is about reference substance acarbose (IC50=7.12 μM) 1.25 times.Experiment shows, the change
Compound has strong suppression alpha-glucosidase activity, has preferable effect of lowering blood sugar.The present invention resists for research and development are new
Diabetes medicament provides new thinking.
The present inventor also extracts above-described embodiment 3 in obtained chrysoeriol -7-O- β-D-Glucose aldehydic acid
Butyl ester has carried out anti tumor activity in vitro experiment：Mtt assay is widely used in the Activity determination, large-scale of some bioactie agents
Screening anti-tumor medicine, cell toxicity test and tumor radiosensitivity measure etc., have the characteristics that high sensitivity, economic.
Exogenous MTT can be reduced to the bluish violet crystallization first a ceremonial jade-ladle, used in libation of water-insoluble by the succinate dehydrogenase in living cells mitochondria
(Formazan) and be deposited in cell, its absorbance value determined at 490nm wavelength with enzyme-linked immunosorbent assay instrument, can between it is reversed
Reflect living cells quantity.In the range of certain cell number, it is directly proportional to cell number that MTT crystallizes the amount to be formed.By calculating compound
When being 50% to inhibition rate of tumor cell, the concentration of corresponding medicine, referred to as half-inhibition concentration IC50, i.e. half-inhibition concentration,
In general, IC50Numerical value it is smaller, illustrate that the medicine is higher to the inhibitory activity of cell.This experiment is calculated using Bliss methods
Chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester of the present invention has been arrived to human cervical carcinoma cell, ovarian cancer cell and liver
The IC when inhibiting rate of cancer is 50%50Value.Experimental result is shown in Table 4.
Chrysoeriol -7-O- the β of table 4.-D-Glucose aldehydic acid butyl ester extracorporeal suppression tumor cell growing multiplication activity
| Cell line | Ovarian cancer cell SK-OV-3 | Cervical cancer cell HeLa | Liver cancer HEPG-2 |
| IC50(umol/mL) | 15.1±1 | 22.0±2 | 71.3±5 |
As can be seen from Table 4, chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester also has very strong antitumor work
Property, especially there is stronger action effect to oophoroma and cervix cancer.Therefore, it is of the invention also to be swollen for new the resisting of research and development
Tumor medicine provides new thinking.
Although embodiment of the present invention is disclosed as above, it is not restricted in specification and embodiment listed
With it can be applied to various suitable the field of the invention completely, can be easily for those skilled in the art
Other modification is realized, therefore under the universal limited without departing substantially from claim and equivalency range, it is of the invention and unlimited
In specific details and shown here as the legend with description.
Claims (8)
- A kind of 1. chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester, it is characterised in that the chrysoeriol -7-O- β - The structural formula of D-Glucose aldehydic acid butyl ester is：
- 2. a kind of extracting method of chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester as claimed in claim 1, its feature It is, comprises the following steps：1) coarse powder is steeped as raw material using triangle, ethanol is solvent, is extracted using percolation, distilled alcohol solvent, obtains first Medicinal extract；2) add water into first medicinal extract, form suspension, petroleum ether, ethyl acetate, positive fourth are sequentially added into suspension Alcohol is extracted, and concentration butanol extraction liquid is into medicinal extract, as the second medicinal extract；3) second medicinal extract is taken, carries out polyamide column chromatography separation, using water-ethanol as eluant, eluent, gradient elution is carried out, collects The eluent of 50% ethanol water, 50% ethanol water eluent of concentration obtains medicinal extract, as the 3rd medicinal extract；4) the 3rd medicinal extract is taken, carries out polyamide column chromatography separation, using water-methanol as eluant, eluent, gradient elution is carried out, collects The eluent of 60% methanol-water, is concentrated to give yellow powder, and yellow needles knot is obtained through silica gel column chromatography separation and acetone recrystallization Crystalline substance, as target product chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester.
- 3. the extracting method of chrysoeriol-7-O- β as claimed in claim 2-D-Glucose aldehydic acid butyl ester, its feature exist In in step 1), the volume fraction of ethanol is 50~95%, and the usage amount of alcohol solvent steeps the 8~15 of coarse powder weight for triangle Times.
- 4. the extracting method of chrysoeriol-7-O- β as claimed in claim 2-D-Glucose aldehydic acid butyl ester, its feature exist In in step 2), the temperature of extraction is 60-90 DEG C.
- 5. the extracting method of chrysoeriol-7-O- β as claimed in claim 2-D-Glucose aldehydic acid butyl ester, its feature exist In, in step 3), using water and ethanol as eluant, eluent, gradient elution is carried out, 5 gradients is specifically divided into and is eluted, water and ethanol Volume ratio be followed successively by：100:0、100:30、100:50、100:80、100:95.
- 6. the extracting method of chrysoeriol-7-O- β as claimed in claim 5-D-Glucose aldehydic acid butyl ester, its feature exist In, in step 4), using water-methanol as eluant, eluent, gradient elution is carried out, is specifically divided into and is eluted for 6 gradients, water and methanol Volume ratio be respectively：100:0、100:20、100:40、100:60、100:80、0:100.
- 7. the extracting method of chrysoeriol-7-O- β as claimed in claim 5-D-Glucose aldehydic acid butyl ester, its feature exist In in step 4), silica gel column chromatography is separated using chloroform and methanol as eluant, eluent, is carried out gradient elution, is specifically divided into 2 ladders Degree is eluted, and its volume ratio is respectively：7:1 and 3:1.
- 8. a kind of purposes of chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester as claimed in claim 1, its feature exist Anti-oxidation medicine, antioxidation cosmetic product, hypoglycemic is being prepared in, the chrysoeriol -7-O- β-D-Glucose aldehydic acid butyl ester Application on medicine or antineoplastic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710792154.2A CN107501367B (en) | 2017-09-05 | 2017-09-05 | Haloeriol-7-O- β -D-glucuronic acid butyl ester and extraction method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710792154.2A CN107501367B (en) | 2017-09-05 | 2017-09-05 | Haloeriol-7-O- β -D-glucuronic acid butyl ester and extraction method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107501367A true CN107501367A (en) | 2017-12-22 |
| CN107501367B CN107501367B (en) | 2020-06-16 |
Family
ID=60694947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710792154.2A Expired - Fee Related CN107501367B (en) | 2017-09-05 | 2017-09-05 | Haloeriol-7-O- β -D-glucuronic acid butyl ester and extraction method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107501367B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107522762A (en) * | 2017-09-05 | 2017-12-29 | 广西中医药大学 | The O β D glucuronic acids ethyl esters of chrysoeriol 7 and its extracting method and purposes |
| CN109260431A (en) * | 2018-10-24 | 2019-01-25 | 西安惟颐生物科技有限公司 | A kind of cervical vertebra, thoracic vertebrae, lumbar vertebrae maintenance essential oil and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140086520A (en) * | 2012-12-28 | 2014-07-08 | 주식회사 제닉 | Cosmetic composition for reducing red spots of skin |
| CN105534990A (en) * | 2015-12-04 | 2016-05-04 | 广西中医药大学 | Application of cardiospermum halicacabum extract in preparation of medicinal preparations for treating diabetes |
-
2017
- 2017-09-05 CN CN201710792154.2A patent/CN107501367B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140086520A (en) * | 2012-12-28 | 2014-07-08 | 주식회사 제닉 | Cosmetic composition for reducing red spots of skin |
| CN105534990A (en) * | 2015-12-04 | 2016-05-04 | 广西中医药大学 | Application of cardiospermum halicacabum extract in preparation of medicinal preparations for treating diabetes |
Non-Patent Citations (9)
| Title |
|---|
| DUC HUNG NGUYEN ET AL.: "Ellagitannin and flavonoid constituents from Agrimonia pilosa Ledeb. with their protein tyrosine phosphatase and acetylcholinesterase inhibitory activities", 《BIOORGANIC CHEMISTRY》 * |
| HUI-LING CHENG ET AL.: "Antiinflammatory and Antioxidant Flavonoids and Phenols from Cardiospermum halicacabum (倒地鈴 Dào Dì Líng)", 《JOURNAL OF TRADITIONAL AND COMPLEMENTARY MEDICINE》 * |
| HUMA SHAREEF ET AL.: "IN VITRO ANTIMICROBIAL AND PHYTOCHEMICAL ANALYSIS OF CARDIOSPERMUM HALICACABUM L", 《PAK. J. BOT.》 * |
| 李磊: "丝瓜中苷类化合物的分离及其生物活性研究", 《中国优秀博硕士学位论文全文数据库(硕士) 工程科技Ⅰ辑》 * |
| 王锡玉等: "《化工基础》", 30 September 2000, 化学工业出版社 * |
| 西庆男等: "倒地铃化学成分和药理活性研究进展", 《广州化工》 * |
| 靳学远等: "《天然产物降血糖功能性成分研究》", 30 June 2009 * |
| 韦建华等: "壮药三角泡黄酮类化学成分研究", 《中草药》 * |
| 马盼: "壮药三角泡抗2型糖尿病活性部位化学成分研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107522762A (en) * | 2017-09-05 | 2017-12-29 | 广西中医药大学 | The O β D glucuronic acids ethyl esters of chrysoeriol 7 and its extracting method and purposes |
| CN107522762B (en) * | 2017-09-05 | 2020-09-01 | 广西中医药大学 | Chrysanthemum eriodictyon flavin-7-O-beta-D-glucuronic acid ethyl ester and extraction method and application thereof |
| CN109260431A (en) * | 2018-10-24 | 2019-01-25 | 西安惟颐生物科技有限公司 | A kind of cervical vertebra, thoracic vertebrae, lumbar vertebrae maintenance essential oil and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107501367B (en) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Juan-Badaturuge et al. | Antioxidant compounds from a South Asian beverage and medicinal plant, Cassia auriculata | |
| Fan et al. | A rapid, accurate and sensitive method for determination of monosaccharides in different varieties of Osmanthus fragrans Lour by pre-column derivatization with HPLC-MS/MS | |
| CN103070400B (en) | Use of lotus procyanidin as advanced glycosylation end product formation inhibitor | |
| CN104341430B (en) | A kind of soil Radix Glycyrrhizae A and extracting method thereof and purposes | |
| CN104069348A (en) | Sealwort extract as well as preparation method and use thereof | |
| CN105232891B (en) | The preparation method of trilliaceae extract and wherein saponins compound and its preparing the application in anti-ischemic heart medicine | |
| CN108339000A (en) | A kind of panax species extract and its pharmaceutical composition and application | |
| CN111349017B (en) | Process for extracting compound from dendrobium nobile lindl and application thereof | |
| CN107501367A (en) | The O β D glucuronic acids butyl esters of chrysoeriol 7 and its extracting method and purposes | |
| CN107446009A (en) | The O β D glucuronic acid methyl esters of chrysoeriol 7 and its extracting method and purposes | |
| CN110483552A (en) | A kind of monoterpenoid indole alkaloid class compound and the preparation method and application thereof | |
| CN113143811B (en) | Preparation method of peony extract compound liposome | |
| CN102786562B (en) | Pyrrolizidine alkaloids and purpose thereof | |
| CN103739652A (en) | New 23, 29-drop oleanolic acid compound, preparation method thereof and application in preparation of glucosidase inhibitor medicines | |
| CN108948038B (en) | Neopteridine flavonoid compound and application thereof | |
| CN103739653B (en) | A kind of 23-fall oleanane acid compound and preparation method thereof and the purposes in preparing glycosidase inhibitor | |
| CN107522762A (en) | The O β D glucuronic acids ethyl esters of chrysoeriol 7 and its extracting method and purposes | |
| CN103497091B (en) | Compound with tyrosinase inhibitory activity and preparation method thereof | |
| CN104257756B (en) | The application in preparing hypoglycemic medicine of a kind of Cortex Mori fatty oil | |
| KR20150075514A (en) | Antiinflamatory Composition for Comprising Algae Extract Fucoxanthin | |
| CN103641882B (en) | Novel 2,3-dihydroxyl-30-noroleanolic acid as well as preparation method and application thereof in preparing glycosidase inhibitor medicament | |
| CN113004299A (en) | Xanthone compound in mangosteen bark for reducing postprandial blood sugar, and extraction method and application thereof | |
| CN107383122A (en) | The method that α glucosidase inhibitors are extracted from carambola root | |
| CN103613632B (en) | 29-falls volatile oil acid compounds and preparation method thereof and is preparing the application in glycosidase inhibitor | |
| CN106265681A (en) | Compound 2 α, 3 β dihydroxy 23 aldehyde radical olive 12 alkene 28 acid application in preparing glycosidase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200616 Termination date: 20210905 |